Across TCGA pan-cancer cohorts, TAS2R14 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TAS2R14 data layer compared with 21 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher TAS2R14 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TAS2R14 expression acts as an unfavorable survival marker.

BLCA, HNSC, and LUSC are the cancer types where TAS2R14 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.222	0.722	.002	12	view →
HNSC	OS	Median	II,III,IV	0.222	0.710	.031	6	view →
LUSC	DFS	Median	All	0.064	0.791	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: TAS2R14 tumor-vs-normal RNA expression · all TAS2R14 data types